Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 3/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCH | P24723 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29018399 | 0.98 | LMNA (0.37) | LMNAPRKCAPRKCEPRKD3PRKCG | |
| SCHEMBL8972669 | 0.98 | LMNA (0.37) | LMNAPRKCAPRKCEPRKD3PRKCG | |
| SCHEMBL8972824 | 0.98 | LMNA (0.37) | LMNAPRKCAPRKCEPRKD3PRKCG | |
| SCHEMBL8971758 | 0.98 | LMNA (0.37) | LMNAPRKCAPRKCEPRKD3PRKCG | |
| SCHEMBL432739 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB | |
| SCHEMBL7780752 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB | |
| SCHEMBL2855219 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB | |
| SCHEMBL593048 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB | |
| SCHEMBL6589677 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB | |
| SCHEMBL31508942 | 0.81 | ALDH1A1 (0.40) | PRKCAPRKCEPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527420-A | Antibacterial calcium-dependent antibiotic (CDA) analogs and methods of treating bacterial infections | 香港大学 | 2021-10-22 | — | — | CN | disclosed |
| US-20210324009-A1 | ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS | THE UNIVERSITY OF HONG KONG (CN) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210324009-A1 | ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS | ORAI1, CASR, CALCA | LMNA 3351/4885PRKCA 555/4885PRKCE 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.